DUBLIN, IRELAND--(Marketwire - April 08, 2008) - Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has obtained commitments from a select group of institutional investors in the USA to purchase approximately 1.8 million American Depositary Shares at a price of $3.92 per ADS in a registered public offering. This represents a discount of 15% to the closing price on NASDAQ on April 7, 2008. Investors also will receive 5-year warrants to purchase an aggregate of approximately 545,000 American Depositary Shares at an exercise price of $5.54 per share, representing a 41% premium to the placement price. These warrants are callable by the Company if the share price exceeds $11.08 for 20 consecutive trading days.
